3653 results for «358»
3653 results
Challenging TAVI access: exploring transfemoral boundaries and mastering alternative access
20 May 2026 – From EuroPCR 2026
This session investigates the boundaries of transfemoral access for TAVI and strategies to safely extend its use. It also provides a comprehensive review of facilitated transfemoral TAVI techniques and explores alternative access options, offering critical insights for managing challenging TAVI cases.
Multi-device approach to calcified lesions
20 May 2026 – From EuroPCR 2026
Explore a multi-device strategy for tackling complex calcified coronary lesions in this session. It includes case studies on left main trifurcation stenting, resistant calcified nodules treated with orbital atherectomy, severe restenosis, and critical calcifications in challenging anatomies, showcasing advanced techniques for plaque modification and lesion management.
TAVI: head-to-head trials
20 May 2026 – From EuroPCR 2026
This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...
TAVI for aortic regurgitation
20 May 2026 – From EuroPCR 2026
This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.
Lost, crushed, fractured: stent complications in real life
20 May 2026 – From EuroPCR 2026
This session addresses real-world challenges of stent complications including loss, crushing, and fracture during PCI. Through case-based discussions, it explores complex scenarios such as stent dislodgement, embolisation, and management strategies when initial plans evolve into complicated realities.
Transcatheter rescue in cardiogenic shock
20 May 2026 – From EuroPCR 2026
This session presents cutting-edge transcatheter rescue interventions in cardiogenic shock scenarios. It covers emergent valve-in-valve procedures, hybrid approaches for valvular heart disease with heart failure, management of ventricular septal rupture post-myocardial infarction, and percutaneous closure techniques for high-risk patients, emphasizing lifesaving interventional strategies.
Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection
20 May 2026 – From EuroPCR 2026
This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.
Imaging guidance in everyday practice
20 May 2026 – From EuroPCR 2026
This session emphasizes the role of imaging guidance in everyday interventional cardiology practice. Through challenging cases involving exertional chest pain, unusual coronary anatomy, complex left ventricular access, side branch navigation, and IVUS-guided re-intervention, it underscores the critical value of advanced imaging for diagnostic clarity and procedural...
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
